PVI
PCVX icon

Pura Vida Investments’s Vaxcyte PCVX Stock Holding History

Pura Vida Investments’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-61,528
Closed -$2.95M – 143
2022
Q4 		$2.95M Buy
+61,528
New +$2.41M 0.15% 107

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Pura Vida Investments's PCVX Position: Q1 2023 in Review

Pura Vida Investments sold out of Vaxcyte (PCVX) in Q1 2023, closing a stake of 61,528 shares — an estimated $2.95M sold.

Pura Vida Investments first reported a position in PCVX in Q4 2022 and held it in 1 quarter. The position peaked at $2.95M in Q4 2022. 187 funds tracked by Wall St. Rank hold PCVX as of Q1 2023.

  • Pura Vida Investments reported no remaining Vaxcyte position as of Q1 2023 after selling out during the quarter.
  • Pura Vida Investments sold 61,528 Vaxcyte shares in Q1 2023, an estimated $2.95M.
  • Pura Vida Investments first reported a position in Vaxcyte in Q4 2022 and held it in 1 quarter.
  • Pura Vida Investments's Vaxcyte position peaked at $2.95M in Q4 2022.
  • 187 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.